Lönnqvist P A, Bergendahl H T, Eksborg S
Department of Pediatric Anesthesiology and Intensive Care, St. Görans Pediatric Hospital, Karolinska Institute, Stockholm, Sweden.
Anesthesiology. 1994 Nov;81(5):1097-101. doi: 10.1097/00000542-199411000-00002.
alpha 2 Agonists have been shown to produce desirable effects when used as premedication or as an adjunct to general anesthesia in adult patients. Several of these beneficial effects (e.g., reduced anesthetic requirements and analgesia without respiratory depression) would be of great benefit in pediatric anesthesia. Information regarding the use of alpha 2 agonists in children is largely lacking. The aim of this study was to investigate the pharmacokinetics of clonidine after rectal administration in children.
Ten ASA physical status 1 pediatric patients (age 14-48 months, weight 10-20 kg) received 2.5 micrograms.kg-1 of clonidine by the rectal route. Blood samples were taken during a 24-h period after the administration. Plasma levels of clonidine were analyzed by radioimmunoassay and subjected to a computer-aided curve-fitting program (PC Nonlin). To estimate the bioavailability of clonidine the results from the current study were compared with data from a previous study in which the same dose of clonidine was given to a similar patient population by the intravenous route.
Maximum plasma concentration was 0.77 ng.ml-1 (0.62-0.88), time to maximum plasma concentration 51 min (29-70), terminal half-life 12.5 h (8.7-19.5), and bioavailability 95% (73-119) (medians [95% confidence interval]). Plasma concentrations within the adult clinically effective range (0.2-2.0 ng.ml-1) were obtained within 10 min of administration.
Rectal administration of 2.5 micrograms.kg-1 of clonidine in children, approximately 20 min before induction of anesthesia, achieves plasma concentrations within the range known to be clinically effective in adults.
α2激动剂在成年患者中用作术前用药或全身麻醉辅助用药时已显示出良好效果。其中一些有益作用(如降低麻醉需求和镇痛而无呼吸抑制)在小儿麻醉中可能会带来很大益处。关于儿童使用α2激动剂的信息在很大程度上尚属缺乏。本研究的目的是调查儿童直肠给药后可乐定的药代动力学。
10例美国麻醉医师协会(ASA)身体状况为1级的儿科患者(年龄14 - 48个月,体重10 - 20千克)经直肠途径接受2.5微克/千克的可乐定。给药后24小时内采集血样。通过放射免疫分析法分析血浆可乐定水平,并使用计算机辅助曲线拟合程序(PC Nonlin)进行分析。为了估算可乐定的生物利用度,将本研究结果与先前一项研究的数据进行比较,在先前研究中,相同剂量的可乐定通过静脉途径给予了类似的患者群体。
血浆最大浓度为0.77纳克/毫升(0.62 - 0.88),达血浆最大浓度时间为51分钟(29 - 70),终末半衰期为12.5小时(8.7 - 19.5),生物利用度为95%(73 - 119)(中位数[95%置信区间])。给药后10分钟内获得了处于成人临床有效范围(0.2 - 2.0纳克/毫升)内的血浆浓度。
在小儿麻醉诱导前约20分钟经直肠给予2.5微克/千克的可乐定,可使血浆浓度达到已知对成人临床有效的范围内。